From TekinHealthHealthcare Tech Field Notes

The Cigna Group announced a partnership with OpenAI to build AI into clinical workflows at Cigna Healthcare and its Accredo Specialty Pharmacy, starting with cancer care. The first tool gives oncology nurses and case managers an AI-enabled interface that pulls together a patient's clinical, pharmacy, behavioral and benefits data into one view, along with patient-reported information like side effects and preferences. Cigna says the goal is to help clinical teams spot needs and coordinate support between physician visits, under human and clinician oversight. The companies plan to expand the collaboration to other conditions over time.

Why it's notable: It puts a large national payer's AI push directly into oncology case management workflows that clinics and specialty pharmacies already touch, rather than just member-facing chat.

The Blue Cross Blue Shield Association analyzed claims data from 2023 to 2025 and found that as hospitals adopted AI coding tools — ambient scribes and automated chart-scanning software that flag secondary diagnoses — more patients were coded as medically complex without a matching change in the care actually delivered. BCBSA estimates this added $942 million in costs across its plans, with $653 million of that traced to more than 55,000 claims pushed into higher-paying complexity tiers by added secondary diagnoses, averaging about $11,000 per case. BCBSA says the figure excludes cases where documentation reflected genuinely new care. Hospital groups dispute the framing, saying patients are sicker and that AI tools are correcting years of underdocumented complexity.

Why it's notable: Health systems are adopting the same ambient-documentation and coding AI at scale (e.g., the VA's Abridge contract), and a major payer is now using claims data to contest how those tools shift reimbursement — a dispute that will shape audits and contract terms for any practice using AI scribing or coding software.

Precision Neuroscience closed an oversubscribed $250 million Series D led by Pershing Square, the Ackman Oxman Institute and an undisclosed life-sciences investment fund, bringing its total raised since founding in 2021 to $430 million. Its Layer 7 Cortical Interface, a thin-film array of 1,024 electrodes that sits on the brain's surface without penetrating tissue, received FDA 510(k) clearance in 2025 for implantation up to 30 days. The company says it has completed more than 100 patient procedures across 18 medical institutions, including Mount Sinai, University of Chicago Medicine and Penn, and has a commercial partnership with Medtronic. Precision says the new funding will expand its clinical program and support further FDA review.

Why it's notable: It's one of the largest rounds yet for a brain-computer interface company, and one of the few with an FDA-cleared implant already in hospital use rather than confined to research settings, signaling BCI is moving from experimental to clinical faster than expected.

Colorado-based Enveda raised a $311 million Series E led by Catalio Capital Management, reportedly at a $2 billion valuation. That brings its total funding to more than $845 million. Enveda uses AI to identify and rank molecules from plants and microbes as drug candidates. It has three programs in human testing: ENV-294 for atopic dermatitis and asthma, now in Phase 2a; ENV-308 for obesity; and ENV-6949, which targets TL1A for inflammatory bowel disease.

Why it's notable: This is one of the largest private rounds this year for an AI drug-discovery company. It gives Enveda funding for several mid-stage trials, a real test of whether AI-found compounds hold up in patients.

The Department of Veterans Affairs selected Abridge under a five-year, multi-award enterprise contract with a ceiling of $775.72 million to provide ambient AI scribes. Knowtex also holds a seat on the contract. The VA began piloting ambient scribes from both vendors in October 2025. The tool is now available to primary care, behavioral health, physical medicine and rehabilitation, and medical and surgical specialty clinicians at more than 75 VA medical centers. Abridge says its scribe runs on both the VA's legacy VistA/CPRS system and the new Oracle Health federal EHR.

Why it's notable: This is one of the largest single ambient AI deployments in US healthcare, and it spans two different EHR platforms. How it goes at the VA will be a reference point for other large systems deciding whether to scale AI scribes.

Melbourne-based Heidi Health raised $340 million: a $100 million Series C led by Blackbird at a $900 million valuation, plus $240 million in growth investment from General Catalyst. The company says its tools support 2.8 million patient visits a week in 190 countries. Its customers include Beth Israel Lahey Health and NHS England Midlands, which Heidi calls the largest clinical AI procurement in NHS history. Heidi plans to move from documentation into supervised, agent-style tasks it calls an AI Care Partner.

Why it's notable: This is one of the largest rounds yet for an ambient-scribe company outside the US leaders. It shows scribe vendors racing to take on more clinical and administrative work, which clinics will see in upcoming product and pricing choices.

CMS released preliminary payment rates for the 2027 Medicare Clinical Laboratory Fee Schedule on September 21, 2026, showing 1,171 of 1,947 test codes would be paid less than in 2026 under the PAMA private-payer-rate reporting cycle. The agency says the cuts average about 16% overall, with molecular pathology and genomic sequencing codes down roughly 22-23%; reductions would phase in at up to 15% a year from 2027 through 2029. CMS estimates the changes save Medicare about $1 billion a year, while the American Clinical Laboratory Association says the new rates are based on private-payer data from only about 2% of labs that bill Medicare Part B. A 30-day comment period is open, with CMS expecting to finalize rates in November 2026.

Why it's notable: Lab reimbursement funds the diagnostic testing infrastructure clinics and hospitals rely on, and a sustained double-digit cut concentrated in molecular pathology and genomic sequencing codes could affect which tests labs can keep offering.

DeepHealth, a RadNet company, received FDA 510(k) clearance for Chest XRay, formerly ChestView. The computer-aided detection tool finds and localizes suspected lung nodules, consolidation, mediastinal and hilar abnormalities, and pleural abnormalities including pneumothorax. It is reported to be one of the first FDA-cleared chest X-ray AI products built on a foundation model. The company says the CE-marked European version analyzes more than 2.8 million exams a year.

Why it's notable: Foundation-model imaging AI can add new findings faster than single-purpose algorithms. This clearance shows the FDA is accepting that design for one of the most common exams in medicine.

CMS announced that its ACCESS model will add tracks for heart failure, chronic obstructive pulmonary disease, substance use disorder and tobacco cessation starting in spring 2027. ACCESS is a voluntary 10-year Medicare model that pays participants for technology-enabled chronic care between visits. It launched on July 5, 2026, with tracks for hypertension, diabetes, chronic musculoskeletal pain and depression. Full payment depends on patients reaching defined outcomes, such as better blood pressure control. CMS says about 160 organizations joined at launch and that three in four Medicare beneficiaries qualify for at least one track.

Why it's notable: ACCESS is Medicare's main outcome-based payment route for virtual care, remote monitoring and connected-device programs. Adding common high-cost conditions like heart failure and COPD widens the pool of patients whose between-visit care clinics and digital health partners can be paid for.

The FDA granted De Novo authorization to Powerful Medical's PMcardio Queen of Hearts, an AI model that reads 12-lead ECGs for signs of urgent acute coronary syndrome, including STEMI and STEMI equivalents, and alerts clinicians to suspected cases. STAT reported the authorization on September 11 and the company announced it on September 15. The company says the model is backed by more than 20 peer-reviewed studies covering over 40,000 patients, found about twice as many heart attacks as standard care with up to five times fewer false positives, and is already used across more than 150 hospital locations, mostly in Europe.

Why it's notable: Many heart attacks caused by a fully blocked artery don't meet standard STEMI criteria on the ECG. A tool that flags them could get more of these patients to the cath lab faster. De Novo authorizations are rare, and this one creates a new FDA device category for AI ECG models that detect acute, life-threatening heart conditions.

OpenEvidence released a family of medical AI search models on September 3. Three are free to verified clinicians on its website and iOS and Android apps: Osler answers in about five seconds for questions during a visit, Sackett runs a deeper search in about 30 seconds, and Snow does a full literature review in about five minutes. A fourth model, Darwin, is available by application only to research partners such as the National Organization for Rare Disorders. The company says Darwin is the first model to score 100% on the MedQA benchmark and that it will add Darwin's capabilities to the three clinician models as safeguards are validated.

Why it's notable: OpenEvidence is one of the AI reference tools doctors use most. It now lets clinicians choose between fast answers at the point of care and slower, deeper evidence reviews. The benchmark results are the company's own claims and measure exam-style questions, not patient outcomes.

In a memo to providers, UnitedHealthcare listed about 1,700 medical codes that will no longer need prior authorization for services on or after October 1, 2026. The insurer says this is roughly 30% of its preapproval requirements. Healthcare Dive reported that the cuts include more than 800 codes for commercial plans, about 940 for ACA plans, about 120 for Medicare Advantage and dual special needs plans, and 1,400 for Oxford plans, with Medicaid varying by state. The affected services include oncology, cardiology, orthopedics, genetic and lab testing, physical, occupational and speech therapy, chiropractic care, home health and durable medical equipment.

Why it's notable: UnitedHealthcare covers more than 48 million people, so practices should re-check their prior authorization workflows and front-desk rules for these services before October 1. Only about 120 of the codes apply to Medicare Advantage, so the relief is uneven across plan types.

OpenAI announced on September 1, 2026 that ChatGPT for Healthcare now connects to Epic electronic health records, letting clinicians at participating organizations pull a patient's chart into the chatbot for read-only reference. Access requires an organization-level workspace covered by a signed business associate agreement rather than an individual account, and OpenAI says it evaluated the feature with 4,363 physician ratings across 27 clinical use cases, reporting a 99.1% "safe" rate. UCSF Health is OpenAI's named pilot partner for the Epic integration. ChatGPT for Healthcare itself launched in January 2026 with organizations including HCA Healthcare, Cedars-Sinai, Memorial Sloan Kettering, Boston Children's Hospital, AdventHealth and Stanford Medicine Children's Health.

Why it's notable: It is one of the largest sanctioned deployments of a general-purpose chatbot directly against live EHR data, and the roughly 1-in-100 "unsafe" response rate OpenAI itself reports means clinicians should treat its output as a starting point, not a verified answer, on charts that include allergies and medication changes.

Sword Health, a virtual physical therapy company, plans to acquire Headspace's parent company OrangeDot for cash. The deal became public on August 25, 2026, through a filing with the Massachusetts Health Policy Commission. The filing did not give a price. Axios reported the deal at up to about $300 million, far below the roughly $3 billion Headspace was valued at after its 2021 merger with Ginger. Headspace offers therapy, coaching and meditation content and says its app has reached more than 100 million people. Sword formally announced the deal on September 16 and said it expects it to close by early in the fourth quarter.

Why it's notable: A former digital mental health leader is being sold at a fraction of its peak value to an AI-driven virtual care company. The deal shows the category consolidating, and it brings mental health support into the same platform employers already buy for musculoskeletal care.

The FDA's Digital Health Center of Excellence published a discussion paper on how it might regulate medical devices that use generative AI. The paper sets out a two-axis risk framework: how independently a device acts, and how much harm a wrong output could cause. It also proposes competency-based premarket testing that combines benchmarking with clinical confirmation, and it covers postmarket monitoring, foundation models and agentic systems. Comments are due October 19, 2026, under docket FDA-2026-N-7874. The FDA has not yet authorized any generative AI device.

Why it's notable: This is the clearest signal so far of how the FDA may treat LLM-based clinical tools, including chatbots and agents. Those rules will decide which of these tools can be marketed for clinical use and what evidence vendors must show.

At its 2026 Users Group Meeting in Verona, Wisconsin, Epic introduced Agent Factory, a no-code platform for health systems to build, run and monitor AI agents that act across Epic workflows. Organizations can start from about 120 built-in AI features or build their own. Epic says early adopters are using it now, with broader availability in 2027. Epic also announced Curiosity, a predictive tool built on its Cosmos clinical database; real-time prior authorization checks; and UpToDate content inside its clinician assistant, Art.

Why it's notable: Epic is the record system for most large US health systems, so its agent platform will shape how AI automation reaches everyday clinical and administrative work. For many organizations, it will also affect whether separate AI vendors are needed at all.

On August 13, 2026, athenahealth made its AI features, including its own ambient scribe athenaAmbient, generally available across the athenaOne network of more than 170,000 physicians and clinicians. The tool records the patient visit on desktop or iOS and drafts the note. It also suggests possible diagnoses, recommends order types and flags care gaps. athenahealth says the tool is included in the core athenaOne subscription at no extra charge. The company says clinicians using it since late 2025 spend about six fewer minutes per encounter on chart prep and documentation, and that early adopters raised same-day chart completion by up to 30%.

Why it's notable: Independent and small practices on athenaOne now get an ambient scribe as part of their EHR fee instead of paying a separate vendor. This follows Epic in building the scribe into the record system and puts pricing pressure on standalone scribe companies.

CMS approved a New Technology Add-on Payment (NTAP) for Aidoc's CARE Body CT Multi-Triage. The FDA-cleared software flags suspected urgent findings on contrast and non-contrast CT of the chest, abdomen and pelvis. Holland & Knight says this is the first NTAP CMS has granted for an AI-enabled diagnostic tool. Starting October 1, 2026, hospitals can receive the add-on for eligible Medicare fee-for-service inpatient cases for three years, with a reported maximum of $137.53 per case.

Why it's notable: How to pay for AI has been one of the main barriers to hospitals adopting imaging AI. A Medicare add-on for an AI triage tool gives other vendors and hospital finance teams a path to follow.

Twelve US health systems announced a Diagnostic AI Consortium with Aidoc on August 11, 2026. Members are Advocate Health, Cedars-Sinai, Hartford HealthCare, Houston Methodist, Mercy, Mount Sinai, Northwell Health, Northwestern Medicine, Sutter Health, UF Health, University Hospitals of Cleveland and WellSpan Health, which together care for nearly 20 million patients a year. The group plans to co-design AI-assisted diagnostic workflows, measure their effect on safety, quality and time to diagnosis across member sites, and agree on shared evaluation and governance practices. Aidoc is supplying the technology through its CARE foundation model and aiOS platform, and the group expects to share its first results in 2027.

Why it's notable: Health systems usually evaluate imaging AI one site at a time. Here a dozen large systems are pooling evidence on whether it actually speeds diagnosis, which could set the standards other hospitals use when they buy and govern these tools.

RadNet subsidiary DeepHealth received FDA 510(k) clearance on July 30, 2026 for DeepHealth Breast Ultrasound, software that automates lesion detection, characterization and reporting. In a multi-reader study with 16 U.S. board-certified radiologists, the company reports more than 98% lesion localization accuracy, an 8% gain in cancer-detection sensitivity and a 37% cut in interpretation time. It is commercially available in the U.S., and DeepHealth expects to roll it out across RadNet's imaging centers by year end.

Why it's notable: Breast ultrasound is labor-intensive and highly operator-dependent, and it is used more often for women with dense breasts. A cleared tool that drafts findings and reports could ease radiologist workload in breast imaging.

Isomorphic Labs — the Alphabet/DeepMind spinoff — is moving past selling AI tools to pharma and into developing its own drug candidates, with trials targeting oncology, cardiovascular disease, and neurodegenerative disease expected by end of 2026. This sits alongside Google's broader healthcare-AI push: the TxGemma open model family for drug discovery, an AI "co-scientist" for hypothesis generation, and a $1B Google Cloud/Merck AI partnership.

Why it's notable: A hyperscaler moving from "AI-for-pharma tooling" to "AI-native drug developer" is a signal of how far automation is creeping into clinical and therapeutic decision-making.

Johnson & Johnson received FDA de novo authorization on July 22, 2026 for its Ottava robotic surgical system, which builds four robotic arms into the operating table. The authorization covers upper-abdominal and other general surgery procedures including Roux-en-Y gastric bypass, sleeve gastrectomy, cholecystectomy, splenectomy, appendectomy, small bowel resection, fundoplication and hiatal hernia repair. The authorization came about six months after J&J filed. The company says it will launch with select U.S. customers first, and a U.S. trial in inguinal hernia repair is ongoing.

Why it's notable: Ottava is a second major competitor to Intuitive's da Vinci in soft-tissue surgery, after Medtronic's Hugo, which gives hospitals buying robots more choice on price and operating-room footprint.

Candid Health raised a $120 million Series D led by Sixth Street Growth, with Oak HC/FT, 8VC and Y Combinator participating, announced July 21, 2026. The company sells software that automates billing, claims submission, denials and collections for provider groups. It says more than 200 healthcare organizations use it, annual recurring revenue grew 190% year over year, and total funding now exceeds $219 million.

Why it's notable: Investors are putting large sums into automating provider billing as payers use more automation of their own. For clinics, this means more vendors competing to take over claims work that staff do by hand today.

Tempus AI agreed on July 20, 2026 to acquire Personalis for $16.25 per share, valuing the deal at about $1.5 billion. The deal adds Personalis's NeXT Personal minimal residual disease (MRD) blood test, which Tempus has sold under a partnership since 2023, to its AI-driven precision oncology platform. The deal is mainly in stock, with Tempus able to pay up to half in cash. It needs Personalis shareholder and regulatory approval and is expected to close in late 2026 or early 2027.

Why it's notable: MRD testing, which tracks cancer recurrence from blood, is becoming part of routine oncology follow-up. The deal puts one of the more sensitive tests on the market under a large AI and genomic data company that oncologists already order from.

CMS's proposed CY 2027 Medicare Physician Fee Schedule, released July 14, 2026, would pay for remote physiologic monitoring (RPM) and remote therapeutic monitoring (RTM) only when the clinical staff doing the work are employed by the billing practice, not by a contracted vendor. It would also limit the services to established patients, require a separately billed initiating visit before monitoring starts, and revalue the device codes. CMS is also considering bundling the codes into four new G-codes. The same rule carries forward telehealth flexibilities through 2027 and proposes a roughly 1.7% cut to the main conversion factor. Comments were due September 14; if finalized, most provisions take effect January 1, 2027.

Why it's notable: Many practices run RPM through third-party vendors, so the proposal could force them to bring monitoring in-house or drop it. It follows an OIG finding that about 43% of 2022 Medicare RPM patients did not get all three required components.

Chai Discovery, a San Francisco company founded in 2024, announced a $400 million Series C on July 14, 2026 at a $3.8 billion valuation. Index Ventures led the round alongside Kleiner Perkins, Sequoia Capital and Dimension, with OpenAI and Thrive Capital among the returning investors. Chai builds AI models that predict and redesign interactions between molecules. Pharmaceutical companies including Eli Lilly, Novartis and Pfizer use them in preclinical drug design. The company has now raised more than $600 million, across three rounds in under a year.

Why it's notable: This is one of the largest venture rounds for an AI drug-design company, and big drugmakers already use Chai's models. Investors are betting that AI-designed molecules will shorten early drug discovery.

NHS England announced on July 6, 2026 that it will add an AI triage tool to the NHS App. The tool asks patients adaptive questions and directs them to a GP appointment, a pharmacy, A&E, community services or self-care. It is due to reach more than 200,000 patients in its first 12 months and all NHS App users by April 2028, and patients can still contact their practice the usual ways. NHS England says a pilot at a Sussex GP practice cut phone queues by 29%. The announcement is part of a £10 billion, three-year technology program that also expands AI notetaking for staff.

Why it's notable: It is one of the largest national deployments of AI front-door triage in primary care, and a test of whether automated routing can ease the morning phone rush at GP practices at scale.

On June 26, 2026, HHS's Office of the National Coordinator for Health IT (ONC) said the number of health records exchanged through the Trusted Exchange Framework and Common Agreement (TEFCA) has grown from about 10 million to more than 1 billion in less than a year. ONC awarded Alliance Global Tech, a federal IT contractor in Columbia, Maryland, a one-year contract of about $1.3 million to check that TEFCA participants follow the network's rules. The contract can be renewed through 2031, for up to about $5.5 million in total. ONC also said it is doing extra compliance reviews of the 11 Qualified Health Information Networks, a group that now includes eClinicalWorks, Netsmart, Oracle Health and Surescripts, and of their participants.

Why it's notable: TEFCA is becoming the main national route for pulling outside records into a clinic's EHR. The new oversight follows disputes over improper record access, including Epic's lawsuit against Health Gorilla, so participants should expect closer checks on why and how they query records.

On June 25, 2026, UpDoc publicly announced the FDA 510(k) clearance (K253281, granted in December 2025) of UpDoc V1.0. It is prescription software that talks with adults with type 2 diabetes by voice or text and adjusts their insulin within limits set by their physician. The company calls it the first FDA-cleared device to use patient-facing large language models. It says the system is deployed at Cleveland Clinic, Allegheny Health Network and UCSF Health, can order follow-up labs and writes its actions into the EHR. It was cleared as a 510(k) with an insulin dosing program as the predicate device, and it is backed by a small Stanford randomized trial published in JAMA Network Open. STAT reported that the CEO would not say whether the language model itself makes the dosing decisions.

Why it's notable: This is the first regulatory path for an AI that talks directly with patients to adjust a drug between visits, and other developers are likely to follow it. It also leaves open how much of the clinical decision the language model makes and how much fixed dosing rules make.

On June 25, 2026, Aidoc said the FDA granted Breakthrough Device Designation to First Read, software that analyzes chest radiographs and writes a draft radiology report for a radiologist to review and sign. The designation covers four life-threatening findings, and the company says the tool is designed to report on more than 100 findings. It is built on Aidoc's CARE foundation model. Breakthrough designation speeds up FDA review but is not a clearance, and First Read is not yet on the market. It is Aidoc's second breakthrough designation in under a year.

Why it's notable: This is one of the first AI tools meant to write the radiology report itself, not just flag a finding, to enter an expedited FDA pathway. That points to how imaging backlogs and report turnaround times may be handled.

Assort Health raised a $120 million Series C led by Menlo Ventures at a $1.2 billion valuation, announced June 24, 2026, bringing its total funding to more than $222 million. Its voice and text agents answer patient calls and handle scheduling, triage, referrals, intake forms, refills, eligibility checks and payments, and they write encounter details back to the EHR. The company says revenue grew 20-fold over 15 months and that John Muir Health saw a 5% absolute increase in net appointment volume after deploying it.

Why it's notable: AI agents answering the front-desk phone are becoming one of the fastest-growing uses of AI in clinics and specialty practices, and they directly affect access, no-shows and staffing.

Cadence, which runs remote monitoring programs for hypertension, diabetes and heart failure with health systems, raised a $100 million Series C led by Spark Capital at a $1.23 billion valuation, announced June 23, 2026. The company says it works with more than 20 health systems and cares for over 100,000 active patients using home devices such as blood pressure cuffs and its own clinicians. Health systems including Corewell Health, Memorial Hermann and Duke Health invested in the round. CEO Chris Altchek told STAT the company plans to use AI agents to automate clinician work and is talking with the FDA about using agents in its hypertension program.

Why it's notable: It is one of the largest bets on outsourced remote monitoring for health systems. It comes as regulators and insurers such as UnitedHealthcare question whether monthly Medicare remote monitoring payments deliver real care.

At the BIO 2026 convention on June 22, 2026, Insilico Medicine and South Korea's SK Biopharmaceuticals announced a collaboration to find drug candidates for neuroinflammatory, neurodegenerative and rare neurological disorders using Insilico's Pharma.AI platform. Insilico gets up to $18 million in upfront and near-term payments. The total potential value tops $2.5 billion, almost all of it tied to future development, regulatory and sales milestones, plus single-digit royalties. SK Biopharmaceuticals, maker of the epilepsy drug Xcopri, will run late-stage development and commercialization.

Why it's notable: It adds to a run of large pharma deals for AI drug discovery, but the small upfront payment shows buyers are still paying mostly for results rather than promises.

Teladoc Health and Walmart announced on May 28, 2026 that Teladoc's virtual care would be offered nationwide through Walmart's Better Care Services platform. The service covers 24/7 urgent care for conditions like sinus and urinary tract infections, dermatology visits and nutrition counseling. Visits can be billed to insurance or paid in cash at $89, and prescriptions can be sent to Walmart pharmacies. Teladoc had already added its BetterHelp mental health service to the platform in January and said it is moving most members from subscriptions to per-visit arrangements.

Why it's notable: Low-acuity visits that used to go to primary care and urgent care clinics are increasingly sold in retail storefronts at a fixed cash price. Clinics lose those visits and see more care happen outside the patient's regular chart.

Oura introduced its Ring 5 on May 28, 2026, with plans to add a feature that tracks overnight blood pressure patterns and tells users when to see a doctor. The feature shows trends rather than systolic and diastolic readings, and it is sold as a wellness tool without FDA review under the agency's January 2026 wellness guidance. Oura said a separate feature to flag possible hypertension is being studied and will go through the FDA. The launch also added health record import and access to clinicians through Counsel Health and ResMed.

Why it's notable: Clinicians should expect patients to bring in blood pressure trends from rings and watches that no regulator has checked for accuracy. Experts quoted by STAT warned that these unvetted blood pressure features are spreading quickly.

On May 13, 2026, CMS named 29 early adopters for its Electronic Prior Authorization Acceleration initiative, part of its Health Tech Ecosystem effort. They include health systems such as Cleveland Clinic, Providence, Ochsner Health, Sanford Health and Bon Secours Mercy Health; EHR vendors Epic, Oracle, athenahealth, eClinicalWorks, MEDITECH, ModMed and TruBridge; and networks including CommonWell and eHealth Exchange. Participants committed to building electronic prior authorization into clinical and billing systems, replacing fax and portal workflows, and showing clinicians where a request stands. The work is meant to get ready for January 1, 2027, when certain payers must support electronic prior authorization for medical items and services.

Why it's notable: Payers have to support electronic prior authorization by 2027, but clinics only benefit if their EHRs and health systems are wired in too. This puts the major EHR vendors on record committing to that work.

Iowa Gov. Kim Reynolds signed House File 2635 on May 13, 2026, effective July 1, 2026. The law says insurers may not use artificial intelligence as the sole basis for denying, delaying or downgrading medically necessary care, and a human clinical reviewer must be involved. It also removes prior authorization for recommended cancer screenings, sets deadlines for insurers to tell hospitals the status of a claim, and requires clinical explanations when care is denied. The bill passed the Iowa House 87-0 and was opposed mainly by insurers.

Why it's notable: Iowa joined a growing list of states putting rules on insurers' use of AI in prior authorization, which gives clinics grounds to challenge denials that were never reviewed by a clinician.

Roche signed a definitive agreement on May 7, 2026 to acquire Boston-based PathAI for $750 million upfront plus up to $300 million in milestone payments. PathAI makes AI models that analyze patient tissue samples and software for running digital pathology labs; Labcorp had expanded its use of the platform across its anatomic pathology labs earlier in 2026. The two companies had worked together since 2021, including on AI-based companion diagnostics. Roche said PathAI would join its Diagnostics division, with closing expected in the second half of 2026 pending antitrust and regulatory approval.

Why it's notable: One of the largest diagnostics companies is buying an AI pathology platform outright rather than partnering, a sign that AI-assisted slide review is moving into the standard lab product line that hospitals and reference labs buy.

On April 23, 2026, OpenAI launched ChatGPT for Clinicians, a version of ChatGPT for clinical work such as documentation, medical research and care questions, free to US physicians, nurse practitioners, physician assistants and pharmacists who verify their NPI and license. Responses cite journal sources, and eligible questions can earn CME credit. OpenAI also released HealthBench Professional, an open benchmark for clinician chat tasks, and says that before launch it tested nearly 7,000 real clinical conversations, with 99.6% of responses rated accurate and safe.

Why it's notable: A free, citation-backed AI assistant from a major AI lab competes directly with paid clinical reference and search tools. Many clinicians will now have it within easy reach.

On April 23, 2026, IKS Health agreed to acquire TruBridge for $26.25 a share in cash, a deal Fierce Healthcare valued at $557M including debt. TruBridge sells EHR, revenue cycle and coding services to more than 1,500 mostly rural and community hospitals and clinics. The companies say the combined business will serve more than 2,000 healthcare organizations and 150,000 clinicians. The deal closed on July 9, 2026, and existing TruBridge products remain available on their own.

Why it's notable: Many small rural hospitals rely on TruBridge for both their EHR and their billing. Its new owner plans to layer AI-driven revenue cycle services on top.